Abstract:Abstract Background Most studies examining differences in gut microbiota composition between healthy individuals and inflammatory bowel disease (IBD) patients, have been conducted on patients receiving immunosuppressive therapy. Such treatments can modify the gut microbiome and skew research data. The IBDomics cohort is a unique population of newly diagnosed IBD patients. Our aim was to elucidate the microbiota in this cohort compared to healthy controls (HC), and the differences between patients with Crohn’s disease (CD) and ulcerative colitis (UC). Methods Stool samples were collected from 104 patients with CD, 145 patients with UC, within the 1st month after the diagnosis (prior to any IBD treatment), and 49 HC. Patients were classified according to endoscopic activity, using the Simple Endoscopic Score for CD (SES-CD) and the endoscopic subscore of the Mayo index for UC. Shotgun metagenomic sequencing was used to analyze microbiota composition. Shannon index (α-diversity) and Bray-Curtis dissimilarity (β-diversity) were used as tests of within-species diversity and within-group diversity, respectively. Results CD patients had a statistically significant decrease in α-diversity, compared to UC and HC; in addition, an inverse relationship was observed between the severity of CD activity and microbial α-diversity. On the opposite, the UC severity had no impact on α-diversity. β-diversity between pair-wise combinations was reduced in UC vs. HC compared to CD vs. HC. This index increased directly with severity in CD patients, while there was no difference in UC patients based on endoscopic severity (Figure 1). Considering the microbial taxonomic abundance, the greatest differences in UC patients compared to HC were found in Toxoplasma gondii and Gemella morbillorum. Of these two species, the 1st showed a direct relationship with the severity of activity and the 2nd one decreased with disease severity. CD patients had the greatest differences in several species of Adlercreutzia and Shigella genus compared to HC (Table 1). Upon grouping CD patients by disease activity, Adlercreutzia hattorii exhibited a consistent decrease across all activity subgroups compared to HC, while Shigella flexneri displayed a significant increase in CD activity groups without notable variance among them. This suggests that the presence of these bacteria is more closely associated with the intrinsic pathology of CD rather than its severity. Conclusion Newly diagnosed CD patients showed notable differences in microbiota compared to UC patients and HC. However, UC microbiome is relatively close to HC. Most of the species detected in the abundance analysis contribute to dysbiosis: declining beneficial genus like Gemella and Adlercreutzia and enhancing pathogen species.

P1236 Oral microbiota dysbiosis in Inflammatory Bowel Disease patients

P1216 Oral Health status in Inflammatory Bowel Disease patients

The oral-gut axis: Salivary and fecal microbiome dysbiosis in patients with inflammatory bowel disease

Dysbiosis and Ecotypes of the Salivary Microbiome Associated with Inflammatory Bowel Diseases and the Assistance in Diagnosis of Diseases Using Oral Bacterial Profiles.

Oral Microbiome of Crohn's Disease Patients With and Without Oral Manifestations

High-throughput sequencing provides insights into oral microbiota dysbiosis in association with inflammatory bowel disease

P1214 The crosstalk between oral and intestinal microbiota in inflammatory bowel disease patients

The Oral Bacterial Microbiota Facilitates the Stratification for Ulcerative Colitis Patients with Oral Ulcers

P010 Faecal microbiota composition by shotgun metagenomic sequencing approach in a newly diagnosed cohort of inflammatory bowel disease patients: results from the IBDomics project

P1226 Determination of oral and gut mucosal microbiome profiles of patients with treatment-naïve ulcerative colitis

P266 Potential oral microbial markers for differential diagnosis of Crohn’s disease and ulcerative colitis using machine learning model

An (Anti)-Inflammatory Microbiota: Defining the Role in Inflammatory Bowel Disease?

Insight into the Relationship between Oral Microbiota and the Inflammatory Bowel Disease

Dietary Determinants of Metabolic and Gut Microbial Health in Patients with Inflammatory Bowel Disease

Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease

Potential Oral Microbial Markers for Differential Diagnosis of Crohn’s Disease and Ulcerative Colitis Using Machine Learning Models

New Insights into the Role of Oral Microbiota Dysbiosis in the Pathogenesis of Inflammatory Bowel Disease

The Oral Microbiome in Pediatric IBD: A Source of Pathobionts or Biomarkers?

Increased Proportions of Bifidobacterium and the Lactobacillus Group and Loss of Butyrate-Producing Bacteria in Inflammatory Bowel Disease

P1221 Analysis Of Oral And Intestinal Microbiome Of Korean Patients With Crohn's Disease

Microbiome and its relevance to indigenous inflammatory bowel diseases in China